4/10/2013

GlaxoSmithKline China granted Eddingpharm exclusive rights to import, promote, market and distribute breast cancer drug Tykerb, or lapatinib, in mainland China. With capecitabine, Tykerb is used for patients with HER2-positive metastatic breast cancer who previously received anthracycline, a taxane and trastuzumab.

Related Summaries